Kanamab needs to get through probably first the US Food and Drug Administration. I'd like to think that this will be the first of many other therapies. Danayamab, also another monoclonal antibody, is due to readout in the next few months. It showed really impromising amyloid removal in its early phase two studies. Do you think we can now sort of allow ourselves to start getting hopeful for a cure? Or if not at least something that would prevent it from the off?
Back in November, researchers hailed the dawn of a new era of Alzheimer’s therapies. After decades of failure, a clinical trial finally confirmed that a drug, lecanemab, was able to slow cognitive decline in patients with early stages of the disease. The result may have been modest – a reduction in the decline in patients’ overall mental skills by 27% over 18 months – but it could not be more significant in the journey towards better understanding and treating the disease. Ian Sample speaks to Prof Nick Fox about the clinical trial results, if this could be the first of many new Alzheimer’s therapies, and whether we could one day see a cure.. Help support our independent journalism at
theguardian.com/sciencepod